The HPV Prevention and Control Board, founded in 2015, is an independent group of international experts supported by unrestricted grants from the pharmaceutical industry[3] that bring together key professionals, groups and government officials to deal with issues related to screening and prevention programmes for human papillomavirus (HPV) infection, the persistence of which may lead to cervical cancer, the second most common cancer in women living in low-resource settings.

[7] The Board co-ordinates interactions between people related to HPV control and prevention, and provides a forum for discussion.

It advises local policy-makers on starting and expanding HPV vaccination programmes, and taking into consideration recommendations by the WHO, helps with political commitment necessary for their implementation.

Investigations by Colombian authorities, had suggested that, beginning in Carmen del Bolivar in 2012, social media could have contributed to disseminating misinformation on the vaccine resulting in a probably mass psychogenic illness.

[9][15][16] However, more recent research papers have suggested in 2021-2022 that the HPV vaccine (Gardasil) could not be ruled out in the case of Carmen de Bolívar, and that the initial diagnosis of mass psychogenic illness was not supported by scientific evidence.

[19][20] The Board has received grants from the pharmaceutical industry[21] including GlaxoSmithKline Biologicals, Merck, Abbott and Sanofi Pasteur, as well as several universities.